Shilpa Medicare Launches World-First NAFLD Drug

  Published 10 months ago

Shilpa Medicare secured historic approval for NorUDCA, the first-in-class NAFLD therapy, pioneering treatment access in India and globally.

  • NorUDCA shows superior efficacy over placebo, significantly improving liver structure and function in NAFLD patients.
  • NAFLD affects 25% of the global population, with 188 million cases in India alone, needing urgent medical solutions.
  • Shilpa to launch NorUDCA tablets in India immediately, with plans for international regulatory submissions and global availability.
You might like these

India Eases Clean-Air Rules for Plants

Western Carriers Wins Jindal Stainless Logistics Contract

HCC Wins Patna Metro Contracts

RBI May Shift Focus to Call Money Rate

Sobha Ltd. Shares Surge on Strong Earnings

Moneyboxx Finance Expands Rural Lending, Raises Rs 237 Crore

Sugar Stocks Rally on Ethanol Boost

News that matters the most ⚡